DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/pdtt87/uveitis_pipeline) has announced the addition of the "Uveitis Pipeline Highlights - 2014 Update" report to their offering.
The latest report Uveitis Pipeline Highlights - 2014 Update, provides most up-to-date information on key pipeline molecules in the global Uveitis market. It covers emerging therapies for Uveitis in active clinical development stages including early and late stage clinical trials. The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
Clinical Trial Stages:
- The report provides Uveitis pipeline molecules by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
Drug Mechanism Classes:
- The report provides Uveitis pipeline molecules by their dominant mechanism of action. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds.
Company:
- The report provides Uveitis pipeline molecules by the Originator Company.
Short-term Launch Highlights:
- Find out which Uveitis pipeline products will be launched in the US and Ex-US till 2017.
Summary:
- Uveitis phase 3 clinical trial pipeline molecules
- Uveitis phase 2 clinical trial pipeline molecules
- Uveitis phase 1 clinical trial pipeline molecules
- Uveitis preclinical research pipeline molecules
- Uveitis discovery stage pipeline molecules
- Uveitis pipeline molecules short-term launch highlights
For more information visit http://www.researchandmarkets.com/research/pdtt87/uveitis_pipeline
